Is Zimmer Biomet’s Q4 Beat And 2026 Guidance Altering The Investment Case For ZBH?

NodeGuardian

2026-03-16 06:31:37

Abstract generation in progress

Zimmer Biomet Holdings (ZBH) exceeded Q4 2025 expectations with strong adjusted EPS and net sales, driven by growth in knees, hips, and S.E.T. products. The company’s 2026 guidance, projecting 2.5% to 4.5% revenue growth and adjusted EPS of US$8.30 to US$8.45, provides a clearer financial outlook. This performance, alongside a steady US$0.24 quarterly dividend and share repurchases, supports the investment narrative for steady demand in orthopedic procedures, though risks like pricing pressure and acquisition integration remain.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes